NASDAQ:HROWM Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) Stock Price, News & Analysis $26.04 -0.01 (-0.03%) As of 10/8/2025 This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsDividendFinancialsSEC FilingsShort InterestTrendsBuy This Stock About Harrow Health, Inc. 11.875% Senior Notes due 2027 Stock (NASDAQ:HROWM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HROWM alerts:Sign Up Key Stats Today's Range$26.00▼$26.0750-Day Range$25.93▼$26.9052-Week Range$24.90▼$27.70Volume25,777 shsAverage Volume5,688 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Harrow Health, Inc. is a diversified biopharmaceutical company focused on improving patient access to innovative ophthalmic therapies. Through its wholly owned subsidiary ImprimisRx®, Harrow Health develops, manufactures and distributes proprietary compounded and generic eye drop formulations for treating a range of anterior segment eye diseases. The company’s product portfolio addresses conditions such as glaucoma, ocular pain and inflammation, and dry eye, and it leverages a direct‐to‐physician distribution model alongside select pharmacy and specialty pharmacy partnerships. Since its founding, Harrow Health has expanded beyond traditional compounding to pursue the commercialization of branded pharmaceutical candidates and digital therapeutics. These efforts include licensing agreements for novel small‐molecule ocular drugs and the development of proprietary platforms aimed at improving formulation stability and patient compliance. Harrow Health’s business strategy emphasizes rapid commercialization of off‐patent ophthalmic formulations while building a pipeline of differentiated products for long‐term growth. Headquartered in Tampa, Florida, Harrow Health serves healthcare providers and patients across the United States, with additional international reach through a network of third-party distributors. The company’s leadership team combines experience in pharmaceutical development, regulatory affairs and specialty pharmacy operations, under the guidance of Chief Executive Officer Anthony Johnson. In April 2022, Harrow Health issued its 11.875% Senior Notes due 2027 (NASDAQ: HROWM) to support ongoing research and development, marketing initiatives and potential strategic acquisitions within the ophthalmology sector.AI Generated. May Contain Errors. Read More Receive HROWM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow Health, Inc. 11.875% Senior Notes due 2027 and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HROWM Stock News HeadlinesHROWM | Harrow Inc. 11.875% Sr. Notes due 2027 Stock Overview (U.S ...September 5, 2025 | barrons.comHarrow Baby Bonds Yield ReviewAugust 22, 2025 | seekingalpha.comMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also brings new risks for retirement savers. Traditional 401(k)s and IRAs may leave investors more exposed than they realize. That’s why a Trump-backed IRS strategy is gaining attention. It allows everyday Americans to reposition their retirement savings into real assets like gold and silver — offering both protection and potential upside. A new 2025 Wealth Protection Guide explains exactly how it works. | American Alternative (Ad)Harrow Inc. 11.875% Sr. Notes due 2027August 28, 2024 | wsj.comHarrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM)May 19, 2024 | finance.yahoo.comSee More Headlines HROWM Stock Analysis - Frequently Asked Questions How have HROWM shares performed this year? Harrow Health, Inc. 11.875% Senior Notes due 2027's stock was trading at $26.21 at the beginning of the year. Since then, HROWM shares have decreased by 0.6% and is now trading at $26.0410. How do I buy shares of Harrow Health, Inc. 11.875% Senior Notes due 2027? Shares of HROWM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Record date for 7/31 Dividend7/15/2025Ex-Dividend for 7/31 Dividend7/15/2025Dividend Payable7/31/2025Today10/13/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry - Sub-IndustryN/A Current SymbolNASDAQ:HROWM CIK1360214 WebN/A PhoneN/AFaxN/AEmployees125Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:HROWM) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredU.S. Government Sparking Crypto RallyMissed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...Crypto 101 Media | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow Health, Inc. 11.875% Senior Notes due 2027 Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow Health, Inc. 11.875% Senior Notes due 2027 With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.